Inhibition of the electron transport chain and creatine kinase activity by ethylmalonic acid in human skeletal muscle

Ethylmalonic aciduria is a common finding in patients affected by short-chain acyl-CoA dehydrogenase (SCAD) deficiency and other diseases characterized by encephalopathy, muscular symptomatology, and lactic acidemia. Considering that the pathophysiological mechanisms of these disorders are practical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Metabolic brain disease 2006-03, Vol.21 (1), p.11-19
Hauptverfasser: BARSCHAK, Alethea G, FERREIRA, Gustavo Da C, WAJNER, Moacir, ANDRE, Karina R, SCHUCK, Patricia F, VIEGAS, Carolina M, TONIN, Anelise, DUTRA FILHO, Carlos S, WYSE, Angela T. S, WANNMACHER, Clovis M. D, VARGAS, Carmen R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 19
container_issue 1
container_start_page 11
container_title Metabolic brain disease
container_volume 21
creator BARSCHAK, Alethea G
FERREIRA, Gustavo Da C
WAJNER, Moacir
ANDRE, Karina R
SCHUCK, Patricia F
VIEGAS, Carolina M
TONIN, Anelise
DUTRA FILHO, Carlos S
WYSE, Angela T. S
WANNMACHER, Clovis M. D
VARGAS, Carmen R
description Ethylmalonic aciduria is a common finding in patients affected by short-chain acyl-CoA dehydrogenase (SCAD) deficiency and other diseases characterized by encephalopathy, muscular symptomatology, and lactic acidemia. Considering that the pathophysiological mechanisms of these disorders are practically unknown and that lactic acidosis suggest an impairment of energy production, the objective of the present work was to investigate the in vitro effect of ethylmalonic acid (EMA), at concentrations varying from 0.25 to 5.0 mM, on important parameters of energy metabolism in human skeletal muscle, such as the activities of the respiratory chain complexes and of creatine kinase, which are responsible for most of the ATP produced and transferred inside the cell. We verified that EMA significantly inhibited the activity of complex I-III at concentrations as low as 0.25 mM, complex II-III at 1 mM and higher concentrations, and complex II at the concentration of 5 mM. In contrast, complex IV was not inhibited by the acid. Finally, we observed that the activity of creatine kinase was significantly inhibited by EMA at the concentrations of 1 and 5 mM. These results suggest that EMA compromises energy metabolism in human skeletal muscle. In case the in vitro effects detected in the present study also occur in vivo, it is tempting to speculate that they may contribute, at least in part, to explain the hypotonia/myopathy, as well as the increased concentrations of lactic acid present in the patients affected by illnesses in which EMA accumulates.
doi_str_mv 10.1007/s11011-006-9000-y
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68074877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1061591351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-adf2e15075f8b5447aaaf59a5cd6cf107b5fb49fac15155312413daf252114f3</originalsourceid><addsrcrecordid>eNqFkU2L3SAUhqW0dG6n_QHdFCm0u7SeqDFZlqEfAwPdzF5OjBJnjLlVU8i_Hy_3wkA3XcnB530P-hDyHtgXYEx9zQAMoGGsawbGWLO_IAeQijeKd_IlObC-l40SA7sib3J-qAiXMLwmV9ApxUXXHch2G2c_-uLXSFdHy2ypDdaUVOeSMObjmgo1M_pIMU7UJIvFR0sffcRsKZri__qy03Gntsx7WDCs0Zt64SdaQ_O2YKT5sbYWDHTZsgn2LXnlMGT77nJek_sf3-9vfjV3v3_e3ny7awzvVWlwcq0FyZR0_SiFUIjo5IDSTJ1xwNQo3SgGhwYkSMmhFcAndK1sAYTj1-TzufaY1j-bzUUvPhsbAka7bll3PVOir1_xPxCGisn2BH78B3xYtxTrG3Rbd3Jg4gTBGTJpzTlZp4_JL5h2DUyfxOmzOF3F6ZM4vdfMh0vxNi52ek5cTFXg0wXAbDC46sb4_Mz1rOcDKP4Efrah-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221131047</pqid></control><display><type>article</type><title>Inhibition of the electron transport chain and creatine kinase activity by ethylmalonic acid in human skeletal muscle</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>BARSCHAK, Alethea G ; FERREIRA, Gustavo Da C ; WAJNER, Moacir ; ANDRE, Karina R ; SCHUCK, Patricia F ; VIEGAS, Carolina M ; TONIN, Anelise ; DUTRA FILHO, Carlos S ; WYSE, Angela T. S ; WANNMACHER, Clovis M. D ; VARGAS, Carmen R</creator><creatorcontrib>BARSCHAK, Alethea G ; FERREIRA, Gustavo Da C ; WAJNER, Moacir ; ANDRE, Karina R ; SCHUCK, Patricia F ; VIEGAS, Carolina M ; TONIN, Anelise ; DUTRA FILHO, Carlos S ; WYSE, Angela T. S ; WANNMACHER, Clovis M. D ; VARGAS, Carmen R</creatorcontrib><description>Ethylmalonic aciduria is a common finding in patients affected by short-chain acyl-CoA dehydrogenase (SCAD) deficiency and other diseases characterized by encephalopathy, muscular symptomatology, and lactic acidemia. Considering that the pathophysiological mechanisms of these disorders are practically unknown and that lactic acidosis suggest an impairment of energy production, the objective of the present work was to investigate the in vitro effect of ethylmalonic acid (EMA), at concentrations varying from 0.25 to 5.0 mM, on important parameters of energy metabolism in human skeletal muscle, such as the activities of the respiratory chain complexes and of creatine kinase, which are responsible for most of the ATP produced and transferred inside the cell. We verified that EMA significantly inhibited the activity of complex I-III at concentrations as low as 0.25 mM, complex II-III at 1 mM and higher concentrations, and complex II at the concentration of 5 mM. In contrast, complex IV was not inhibited by the acid. Finally, we observed that the activity of creatine kinase was significantly inhibited by EMA at the concentrations of 1 and 5 mM. These results suggest that EMA compromises energy metabolism in human skeletal muscle. In case the in vitro effects detected in the present study also occur in vivo, it is tempting to speculate that they may contribute, at least in part, to explain the hypotonia/myopathy, as well as the increased concentrations of lactic acid present in the patients affected by illnesses in which EMA accumulates.</description><identifier>ISSN: 0885-7490</identifier><identifier>EISSN: 1573-7365</identifier><identifier>DOI: 10.1007/s11011-006-9000-y</identifier><identifier>PMID: 16773466</identifier><identifier>CODEN: MBDIEE</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Acidosis, Lactic - metabolism ; Adenosine Triphosphate - metabolism ; Adolescent ; Adult ; Biological and medical sciences ; Cerebral circulation. Blood-brain barrier. Choroid plexus. Cerebrospinal fluid. Circumventricular organ. Meninges ; Creatine Kinase - metabolism ; Electron Transport Chain Complex Proteins - antagonists &amp; inhibitors ; Electron Transport Chain Complex Proteins - metabolism ; Electron Transport Complex I - antagonists &amp; inhibitors ; Electron Transport Complex I - metabolism ; Electron Transport Complex II - antagonists &amp; inhibitors ; Electron Transport Complex II - metabolism ; Electron Transport Complex III - antagonists &amp; inhibitors ; Electron Transport Complex III - metabolism ; Electron Transport Complex IV - antagonists &amp; inhibitors ; Electron Transport Complex IV - metabolism ; Energy Metabolism - drug effects ; Energy Metabolism - physiology ; Enzyme Activation - drug effects ; Fundamental and applied biological sciences. Psychology ; Humans ; In Vitro Techniques ; Malonates - pharmacology ; Medical sciences ; Muscle, Skeletal - drug effects ; Muscle, Skeletal - enzymology ; Neurology ; Vascular diseases and vascular malformations of the nervous system ; Vertebrates: nervous system and sense organs</subject><ispartof>Metabolic brain disease, 2006-03, Vol.21 (1), p.11-19</ispartof><rights>2006 INIST-CNRS</rights><rights>Springer Science+Business Media, Inc. 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-adf2e15075f8b5447aaaf59a5cd6cf107b5fb49fac15155312413daf252114f3</citedby><cites>FETCH-LOGICAL-c387t-adf2e15075f8b5447aaaf59a5cd6cf107b5fb49fac15155312413daf252114f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18083917$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16773466$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BARSCHAK, Alethea G</creatorcontrib><creatorcontrib>FERREIRA, Gustavo Da C</creatorcontrib><creatorcontrib>WAJNER, Moacir</creatorcontrib><creatorcontrib>ANDRE, Karina R</creatorcontrib><creatorcontrib>SCHUCK, Patricia F</creatorcontrib><creatorcontrib>VIEGAS, Carolina M</creatorcontrib><creatorcontrib>TONIN, Anelise</creatorcontrib><creatorcontrib>DUTRA FILHO, Carlos S</creatorcontrib><creatorcontrib>WYSE, Angela T. S</creatorcontrib><creatorcontrib>WANNMACHER, Clovis M. D</creatorcontrib><creatorcontrib>VARGAS, Carmen R</creatorcontrib><title>Inhibition of the electron transport chain and creatine kinase activity by ethylmalonic acid in human skeletal muscle</title><title>Metabolic brain disease</title><addtitle>Metab Brain Dis</addtitle><description>Ethylmalonic aciduria is a common finding in patients affected by short-chain acyl-CoA dehydrogenase (SCAD) deficiency and other diseases characterized by encephalopathy, muscular symptomatology, and lactic acidemia. Considering that the pathophysiological mechanisms of these disorders are practically unknown and that lactic acidosis suggest an impairment of energy production, the objective of the present work was to investigate the in vitro effect of ethylmalonic acid (EMA), at concentrations varying from 0.25 to 5.0 mM, on important parameters of energy metabolism in human skeletal muscle, such as the activities of the respiratory chain complexes and of creatine kinase, which are responsible for most of the ATP produced and transferred inside the cell. We verified that EMA significantly inhibited the activity of complex I-III at concentrations as low as 0.25 mM, complex II-III at 1 mM and higher concentrations, and complex II at the concentration of 5 mM. In contrast, complex IV was not inhibited by the acid. Finally, we observed that the activity of creatine kinase was significantly inhibited by EMA at the concentrations of 1 and 5 mM. These results suggest that EMA compromises energy metabolism in human skeletal muscle. In case the in vitro effects detected in the present study also occur in vivo, it is tempting to speculate that they may contribute, at least in part, to explain the hypotonia/myopathy, as well as the increased concentrations of lactic acid present in the patients affected by illnesses in which EMA accumulates.</description><subject>Acidosis, Lactic - metabolism</subject><subject>Adenosine Triphosphate - metabolism</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cerebral circulation. Blood-brain barrier. Choroid plexus. Cerebrospinal fluid. Circumventricular organ. Meninges</subject><subject>Creatine Kinase - metabolism</subject><subject>Electron Transport Chain Complex Proteins - antagonists &amp; inhibitors</subject><subject>Electron Transport Chain Complex Proteins - metabolism</subject><subject>Electron Transport Complex I - antagonists &amp; inhibitors</subject><subject>Electron Transport Complex I - metabolism</subject><subject>Electron Transport Complex II - antagonists &amp; inhibitors</subject><subject>Electron Transport Complex II - metabolism</subject><subject>Electron Transport Complex III - antagonists &amp; inhibitors</subject><subject>Electron Transport Complex III - metabolism</subject><subject>Electron Transport Complex IV - antagonists &amp; inhibitors</subject><subject>Electron Transport Complex IV - metabolism</subject><subject>Energy Metabolism - drug effects</subject><subject>Energy Metabolism - physiology</subject><subject>Enzyme Activation - drug effects</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Malonates - pharmacology</subject><subject>Medical sciences</subject><subject>Muscle, Skeletal - drug effects</subject><subject>Muscle, Skeletal - enzymology</subject><subject>Neurology</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0885-7490</issn><issn>1573-7365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkU2L3SAUhqW0dG6n_QHdFCm0u7SeqDFZlqEfAwPdzF5OjBJnjLlVU8i_Hy_3wkA3XcnB530P-hDyHtgXYEx9zQAMoGGsawbGWLO_IAeQijeKd_IlObC-l40SA7sib3J-qAiXMLwmV9ApxUXXHch2G2c_-uLXSFdHy2ypDdaUVOeSMObjmgo1M_pIMU7UJIvFR0sffcRsKZri__qy03Gntsx7WDCs0Zt64SdaQ_O2YKT5sbYWDHTZsgn2LXnlMGT77nJek_sf3-9vfjV3v3_e3ny7awzvVWlwcq0FyZR0_SiFUIjo5IDSTJ1xwNQo3SgGhwYkSMmhFcAndK1sAYTj1-TzufaY1j-bzUUvPhsbAka7bll3PVOir1_xPxCGisn2BH78B3xYtxTrG3Rbd3Jg4gTBGTJpzTlZp4_JL5h2DUyfxOmzOF3F6ZM4vdfMh0vxNi52ek5cTFXg0wXAbDC46sb4_Mz1rOcDKP4Efrah-w</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>BARSCHAK, Alethea G</creator><creator>FERREIRA, Gustavo Da C</creator><creator>WAJNER, Moacir</creator><creator>ANDRE, Karina R</creator><creator>SCHUCK, Patricia F</creator><creator>VIEGAS, Carolina M</creator><creator>TONIN, Anelise</creator><creator>DUTRA FILHO, Carlos S</creator><creator>WYSE, Angela T. S</creator><creator>WANNMACHER, Clovis M. D</creator><creator>VARGAS, Carmen R</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20060301</creationdate><title>Inhibition of the electron transport chain and creatine kinase activity by ethylmalonic acid in human skeletal muscle</title><author>BARSCHAK, Alethea G ; FERREIRA, Gustavo Da C ; WAJNER, Moacir ; ANDRE, Karina R ; SCHUCK, Patricia F ; VIEGAS, Carolina M ; TONIN, Anelise ; DUTRA FILHO, Carlos S ; WYSE, Angela T. S ; WANNMACHER, Clovis M. D ; VARGAS, Carmen R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-adf2e15075f8b5447aaaf59a5cd6cf107b5fb49fac15155312413daf252114f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Acidosis, Lactic - metabolism</topic><topic>Adenosine Triphosphate - metabolism</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cerebral circulation. Blood-brain barrier. Choroid plexus. Cerebrospinal fluid. Circumventricular organ. Meninges</topic><topic>Creatine Kinase - metabolism</topic><topic>Electron Transport Chain Complex Proteins - antagonists &amp; inhibitors</topic><topic>Electron Transport Chain Complex Proteins - metabolism</topic><topic>Electron Transport Complex I - antagonists &amp; inhibitors</topic><topic>Electron Transport Complex I - metabolism</topic><topic>Electron Transport Complex II - antagonists &amp; inhibitors</topic><topic>Electron Transport Complex II - metabolism</topic><topic>Electron Transport Complex III - antagonists &amp; inhibitors</topic><topic>Electron Transport Complex III - metabolism</topic><topic>Electron Transport Complex IV - antagonists &amp; inhibitors</topic><topic>Electron Transport Complex IV - metabolism</topic><topic>Energy Metabolism - drug effects</topic><topic>Energy Metabolism - physiology</topic><topic>Enzyme Activation - drug effects</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Malonates - pharmacology</topic><topic>Medical sciences</topic><topic>Muscle, Skeletal - drug effects</topic><topic>Muscle, Skeletal - enzymology</topic><topic>Neurology</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BARSCHAK, Alethea G</creatorcontrib><creatorcontrib>FERREIRA, Gustavo Da C</creatorcontrib><creatorcontrib>WAJNER, Moacir</creatorcontrib><creatorcontrib>ANDRE, Karina R</creatorcontrib><creatorcontrib>SCHUCK, Patricia F</creatorcontrib><creatorcontrib>VIEGAS, Carolina M</creatorcontrib><creatorcontrib>TONIN, Anelise</creatorcontrib><creatorcontrib>DUTRA FILHO, Carlos S</creatorcontrib><creatorcontrib>WYSE, Angela T. S</creatorcontrib><creatorcontrib>WANNMACHER, Clovis M. D</creatorcontrib><creatorcontrib>VARGAS, Carmen R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolic brain disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BARSCHAK, Alethea G</au><au>FERREIRA, Gustavo Da C</au><au>WAJNER, Moacir</au><au>ANDRE, Karina R</au><au>SCHUCK, Patricia F</au><au>VIEGAS, Carolina M</au><au>TONIN, Anelise</au><au>DUTRA FILHO, Carlos S</au><au>WYSE, Angela T. S</au><au>WANNMACHER, Clovis M. D</au><au>VARGAS, Carmen R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of the electron transport chain and creatine kinase activity by ethylmalonic acid in human skeletal muscle</atitle><jtitle>Metabolic brain disease</jtitle><addtitle>Metab Brain Dis</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>21</volume><issue>1</issue><spage>11</spage><epage>19</epage><pages>11-19</pages><issn>0885-7490</issn><eissn>1573-7365</eissn><coden>MBDIEE</coden><abstract>Ethylmalonic aciduria is a common finding in patients affected by short-chain acyl-CoA dehydrogenase (SCAD) deficiency and other diseases characterized by encephalopathy, muscular symptomatology, and lactic acidemia. Considering that the pathophysiological mechanisms of these disorders are practically unknown and that lactic acidosis suggest an impairment of energy production, the objective of the present work was to investigate the in vitro effect of ethylmalonic acid (EMA), at concentrations varying from 0.25 to 5.0 mM, on important parameters of energy metabolism in human skeletal muscle, such as the activities of the respiratory chain complexes and of creatine kinase, which are responsible for most of the ATP produced and transferred inside the cell. We verified that EMA significantly inhibited the activity of complex I-III at concentrations as low as 0.25 mM, complex II-III at 1 mM and higher concentrations, and complex II at the concentration of 5 mM. In contrast, complex IV was not inhibited by the acid. Finally, we observed that the activity of creatine kinase was significantly inhibited by EMA at the concentrations of 1 and 5 mM. These results suggest that EMA compromises energy metabolism in human skeletal muscle. In case the in vitro effects detected in the present study also occur in vivo, it is tempting to speculate that they may contribute, at least in part, to explain the hypotonia/myopathy, as well as the increased concentrations of lactic acid present in the patients affected by illnesses in which EMA accumulates.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>16773466</pmid><doi>10.1007/s11011-006-9000-y</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0885-7490
ispartof Metabolic brain disease, 2006-03, Vol.21 (1), p.11-19
issn 0885-7490
1573-7365
language eng
recordid cdi_proquest_miscellaneous_68074877
source MEDLINE; SpringerNature Journals
subjects Acidosis, Lactic - metabolism
Adenosine Triphosphate - metabolism
Adolescent
Adult
Biological and medical sciences
Cerebral circulation. Blood-brain barrier. Choroid plexus. Cerebrospinal fluid. Circumventricular organ. Meninges
Creatine Kinase - metabolism
Electron Transport Chain Complex Proteins - antagonists & inhibitors
Electron Transport Chain Complex Proteins - metabolism
Electron Transport Complex I - antagonists & inhibitors
Electron Transport Complex I - metabolism
Electron Transport Complex II - antagonists & inhibitors
Electron Transport Complex II - metabolism
Electron Transport Complex III - antagonists & inhibitors
Electron Transport Complex III - metabolism
Electron Transport Complex IV - antagonists & inhibitors
Electron Transport Complex IV - metabolism
Energy Metabolism - drug effects
Energy Metabolism - physiology
Enzyme Activation - drug effects
Fundamental and applied biological sciences. Psychology
Humans
In Vitro Techniques
Malonates - pharmacology
Medical sciences
Muscle, Skeletal - drug effects
Muscle, Skeletal - enzymology
Neurology
Vascular diseases and vascular malformations of the nervous system
Vertebrates: nervous system and sense organs
title Inhibition of the electron transport chain and creatine kinase activity by ethylmalonic acid in human skeletal muscle
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T09%3A38%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20the%20electron%20transport%20chain%20and%20creatine%20kinase%20activity%20by%20ethylmalonic%20acid%20in%20human%20skeletal%20muscle&rft.jtitle=Metabolic%20brain%20disease&rft.au=BARSCHAK,%20Alethea%20G&rft.date=2006-03-01&rft.volume=21&rft.issue=1&rft.spage=11&rft.epage=19&rft.pages=11-19&rft.issn=0885-7490&rft.eissn=1573-7365&rft.coden=MBDIEE&rft_id=info:doi/10.1007/s11011-006-9000-y&rft_dat=%3Cproquest_cross%3E1061591351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221131047&rft_id=info:pmid/16773466&rfr_iscdi=true